Articles tagged with Lung Cancer
Comprehensive exploration of living organisms, biological systems, and life processes across all scales from molecules to ecosystems. Encompasses cutting-edge research in biology, genetics, molecular biology, ecology, biochemistry, microbiology, botany, zoology, evolutionary biology, genomics, and biotechnology. Investigates cellular mechanisms, organism development, genetic inheritance, biodiversity conservation, metabolic processes, protein synthesis, DNA sequencing, CRISPR gene editing, stem cell research, and the fundamental principles governing all forms of life on Earth.
Comprehensive medical research, clinical studies, and healthcare sciences focused on disease prevention, diagnosis, and treatment. Encompasses clinical medicine, public health, pharmacology, epidemiology, medical specialties, disease mechanisms, therapeutic interventions, healthcare innovation, precision medicine, telemedicine, medical devices, drug development, clinical trials, patient care, mental health, nutrition science, health policy, and the application of medical science to improve human health, wellbeing, and quality of life across diverse populations.
Comprehensive investigation of human society, behavior, relationships, and social structures through systematic research and analysis. Encompasses psychology, sociology, anthropology, economics, political science, linguistics, education, demography, communications, and social research methodologies. Examines human cognition, social interactions, cultural phenomena, economic systems, political institutions, language and communication, educational processes, population dynamics, and the complex social, cultural, economic, and political forces shaping human societies, communities, and civilizations throughout history and across the contemporary world.
Fundamental study of the non-living natural world, matter, energy, and physical phenomena governing the universe. Encompasses physics, chemistry, earth sciences, atmospheric sciences, oceanography, materials science, and the investigation of physical laws, chemical reactions, geological processes, climate systems, and planetary dynamics. Explores everything from subatomic particles and quantum mechanics to planetary systems and cosmic phenomena, including energy transformations, molecular interactions, elemental properties, weather patterns, tectonic activity, and the fundamental forces and principles underlying the physical nature of reality.
Practical application of scientific knowledge and engineering principles to solve real-world problems and develop innovative technologies. Encompasses all engineering disciplines, technology development, computer science, artificial intelligence, environmental sciences, agriculture, materials applications, energy systems, and industrial innovation. Bridges theoretical research with tangible solutions for infrastructure, manufacturing, computing, communications, transportation, construction, sustainable development, and emerging technologies that advance human capabilities, improve quality of life, and address societal challenges through scientific innovation and technological progress.
Study of the practice, culture, infrastructure, and social dimensions of science itself. Addresses how science is conducted, organized, communicated, and integrated into society. Encompasses research funding mechanisms, scientific publishing systems, peer review processes, academic ethics, science policy, research institutions, scientific collaboration networks, science education, career development, research programs, scientific methods, science communication, and the sociology of scientific discovery. Examines the human, institutional, and cultural aspects of scientific enterprise, knowledge production, and the translation of research into societal benefit.
Comprehensive study of the universe beyond Earth, encompassing celestial objects, cosmic phenomena, and space exploration. Includes astronomy, astrophysics, planetary science, cosmology, space physics, astrobiology, and space technology. Investigates stars, galaxies, planets, moons, asteroids, comets, black holes, nebulae, exoplanets, dark matter, dark energy, cosmic microwave background, stellar evolution, planetary formation, space weather, solar system dynamics, the search for extraterrestrial life, and humanity's efforts to explore, understand, and unlock the mysteries of the cosmos through observation, theory, and space missions.
Comprehensive examination of tools, techniques, methodologies, and approaches used across scientific disciplines to conduct research, collect data, and analyze results. Encompasses experimental procedures, analytical methods, measurement techniques, instrumentation, imaging technologies, spectroscopic methods, laboratory protocols, observational studies, statistical analysis, computational methods, data visualization, quality control, and methodological innovations. Addresses the practical techniques and theoretical frameworks enabling scientists to investigate phenomena, test hypotheses, gather evidence, ensure reproducibility, and generate reliable knowledge through systematic, rigorous investigation across all areas of scientific inquiry.
Study of abstract structures, patterns, quantities, relationships, and logical reasoning through pure and applied mathematical disciplines. Encompasses algebra, calculus, geometry, topology, number theory, analysis, discrete mathematics, mathematical logic, set theory, probability, statistics, and computational mathematics. Investigates mathematical structures, theorems, proofs, algorithms, functions, equations, and the rigorous logical frameworks underlying quantitative reasoning. Provides the foundational language and tools for all scientific fields, enabling precise description of natural phenomena, modeling of complex systems, and the development of technologies across physics, engineering, computer science, economics, and all quantitative sciences.
A recent article describes clinical trials targeting TRK fusions in various cancer types, including lung, breast, and melanoma. The TRK family of genes can cause cancer when improperly fused with other nearby genes.
Researchers found that lung cancer cells sever protein ties, allowing them to break loose and spread. Targeting this process could stop lung cancer from spreading by keeping cells stuck together.
Researchers discovered new gene fusions in lung cancers with worse outcomes than patients with fewer fusions. The study identified several new genetic anomalies, including those found in smokers, which could be targets for developing new treatments.
Researchers found that a high-calorie diet before tumor onset can trigger ER stress, hindering tumor growth. The study identified a specific protein, FKBP10, as a potential therapeutic target, which could selectively inhibit cancer cell proliferation without damaging healthy tissues.
Researchers used targeted NGS to identify genetic alterations in genes involved in DNA repair, cell survival, and proliferation pathways. The study found that accumulated mutations correlate with tumor progression and decreased survival rates in patients with advanced malignant lung cancer. The results highlight the potential of NGS to...
A nationwide survey of 2200 French adults reveals significant knowledge gaps about lung cancer, including misconceptions about screening, treatment options, and prognosis. The study emphasizes the need for public education to address these gaps and improve outcomes.
A new study by the American Cancer Society finds that cigarette smoking causes about three in ten cancer deaths in the United States. The study concludes that reducing smoking prevalence as rapidly as possible should be a top priority for US public health efforts to prevent future cancer deaths.
A recent study published in the New England Journal of Medicine found that crizotinib significantly improves symptoms and delays cancer growth in patients with ALK-positive non-small cell lung cancer. The trial involved 343 previously untreated patients, showing promising results without unexpected side effects.
A new lung cancer risk model, PLCOm2012, refines decisions to screen individuals for annual CT scans, identifying a risk threshold for selecting high-risk smokers. The study found that this threshold resulted in higher sensitivity and specificity than the USPSTF criteria.
Improvements in cancer survival mean half of all people diagnosed today will survive at least 10 years, compared to a quarter 40 years ago. However, cancers like lung, stomach, and pancreatic cancer remain extremely challenging to treat.
A Women's Health Initiative study found that removing ovaries lowers the risk of pelvic organ prolapse in women after menopause. Age, rather than menopause, is a stronger predictor of the condition.
Researchers at Salk Institute develop a powerful dual-drug therapy that doubles the survival rate of mice with lung cancer and halts cancer in pancreatic cells. The treatment combines two existing drugs, Zometa and rapamycin, to successfully target KRAS mutation.
A phase I/II clinical trial has demonstrated that rociletinib, a new oral EGFR inhibitor, can respond to treatment-resistant advanced non-small cell lung cancer, including those with the T790M resistance mutation. The overall response rate was 46%, and disease control rate was 84% among patients who received the pivotal dose.
African Americans and Hispanics are less likely to receive effective radiation therapy for early-stage lung cancer, according to a study. The study highlights significant disparities in treatment options based on hospital type and insurance status.
A novel medical-imaging technology called TexRAD has been shown to enable early diagnosis of bowel-cancer patients not responding to standard cancer therapy. The technology analyzes the texture of tumors, distinguishing patients with good prognosis from those with poor prognosis.
A pooled analysis of five cohort studies found that smoking before first cancer diagnosis increases risk of developing a second smoking-related cancer. Smoking survivors have up to a 5-fold higher risk of developing a second primary smoking-associated cancer compared to non-smokers.
Researchers found that pretreatment interstitial lung disease significantly increases the risk of developing symptomatic and severe radiation pneumonitis in stage I non-small cell lung cancer patients treated with stereotactic body radiation therapy. The study's results suggest that clinicians should be cautious when considering SBRT f...
A new study from Dartmouth researchers suggests that lung cancer screening using annual low-dose CT scans can be done in a cost-effective manner, particularly for adults aged 65-75. The study found that the screening test produces $81,000 in quality-adjusted life years per dollar spent.
A new study published in the Journal of Clinical Investigation found that tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. These cells produce molecules promoting inflammation, and their role is crucial for bolstering anti-tumor immune responses.
A new analysis of NLST results concludes that CT lung screening is cost-effective in aging smokers, but its implementation will depend on various factors. The ratio of costs per quality-adjusted life-year added was $81,000, below the $100,000 threshold.
A risk stratification model based on lymph node characteristics confirms the true lack of lung cancer in sampled nodes. The model categorizes low-risk nodes with a high chance of being truly negative, while high-risk nodes have a significant false-negative rate.
Patients with emergency-diagnosed lung cancer reported difficulties in seeing their general practitioner (GP), including lack of confidence and fear of diagnosis. Nearly half of the patients delayed seeking medical attention for over 12 weeks, highlighting the need for improved patient education and rapid-access diagnostic clinics.
A team of researchers has made a breakthrough in early diagnosis of invasive cancers, detecting lung cancer in patients at risk through circulating cancer cells in their bloodstream. This method could enable early surgical intervention and potentially improve patient survival.
Research reveals that minimally invasive adenocarcinoma (MIA) and adenocarcinoma in-situ (AIS) lung cancer patients have comparable five-year disease-free and overall survival rates of 97.7%. This finding suggests that tumor sub-classification may not provide additional prognostic information for patients with tumors ≤3 cm in size.
Research found that post-operative radiation therapy improved overall survival for patients with resected NSCLC, with a median survival time of 42 months compared to 38 months without PORT. Factors associated with better survival included female gender, adenocarcinoma histology, and younger age.
A 10-year analysis of data from an institutional patient registry indicates that 79% of tumors are controlled locally for early stage lung cancer patients treated with SBRT. The treatment resulted in minimal toxicity, with no grade 4 or 5 events recorded.
A study analyzing Medicare claims found that biopsies accounted for 43.1% of $38.3 million in diagnostic costs for patients with ultimately negative lung cancer diagnoses. Lung biopsies were also the most expensive test, with a median cost of $3,784 and an average cost including complications of $37,745.
Research shows that primary care providers who know guideline recommendations for low-dose computed tomography (LDCT) screening are more likely to order LDCT for high-risk individuals. This knowledge gap is highlighted by a survey of over 200 primary care providers, which found that 48% knew three or more guideline components.
Researchers found that erlotinib, a targeted drug for advanced-stage lung cancer, can increase the aggressiveness of tumors in early-stage patients, leading to accelerated growth and decreased survival rates. The study suggests combining an EGFR inhibitor with a Notch inhibitor may overcome this effect.
A novel software application, CANARY, can automatically analyze high-resolution CT images to classify early-stage non-small cell lung cancer patients into risk groups. The tool was developed at Mayo Clinic and demonstrated accurate stratification of patients into categories with different 5-year disease-free survival outcomes.
A European multicenter harmonization study reveals that standardized semi-quantitative anaplastic lymphoma kinase (ALK) IHC is reliable and comparable to FISH testing for detecting ALK protein expression. The study showed 100% concordance among institutions on 15 well-characterized NSCLC specimens, making IHC a potential stand-alone test.
Researchers at UTMB have discovered three small-molecule compounds that activate Bax and induce high levels of cell death in lung cancer cells without harming noncancerous tissues. These findings represent a new class of anticancer drugs with a unique therapeutic target for the treatment of cancers expressing Bax, including lung cancer.
Researchers identified 149 metabolites with altered concentrations in patients with non-small cell lung cancer compared to those at risk but without the disease. The study suggests a potential diagnostic biomarker for early lung cancer detection.
A large-scale population-based study found that removing the entire lobe of lung may offer better overall survival compared to partial resection and stereotactic ablative radiotherapy. The study also suggests that SABR may be a suitable alternative to surgery for elderly patients with multiple medical problems.
Researchers found that family doctors may not be detecting lung cancer signs promptly enough, with one in seven patients dying within three months. Chest x-rays performed in primary care had lower early death rates, but frequent GP visits increased the risk.
CNIO researchers found that the simultaneous inhibition of Cdk4 and Cdk6 is more effective than individual inhibition in reducing tumour growth and promoting aggressive tumours in mice. The study also revealed that the combined activation of both oncogenes leads to uncontrolled cell division and an increased risk of developing leukemia.
Researchers discovered that lung cancers can exist undetected for many years due to unique genetic faults in separate areas of the tumor. The study highlights the need for better early detection methods to improve treatment outcomes, as two-thirds of patients are diagnosed with advanced disease when treatments are less effective.
A study published in Science found that sequencing a single region of a localized tumor can identify most cancer-driving genomic aberrations. The researchers identified 20 known cancer gene mutations across all regions of the same tumor, suggesting a potential connection to relapse.
Scientists at the University of Kansas have developed a miniaturized biomedical testing device for exosomes, promising earlier detection and improved survival rates for patients. The lab-on-a-chip technology uses magnetic beads to isolate exosomes from plasma samples, enabling minimally invasive and cost-effective cancer diagnosis.
A new virtual breast test using ultrasound elastography could significantly improve cancer detection accuracy, especially for women with suspicious mammograms.
A phase 1 clinical trial of crizotinib against ROS1-positive lung cancer showed a 72% response rate and 19.2 months progression-free survival, suggesting potential for durable action against this subtype of lung cancer.
Phase II data showed dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer. HER2 inhibition also shows promise in HER2-positive non-small cell lung cancer, with a 21% overall response rate in patients treated with neratinib and temsirolimus.
A Korean study showed that patients with low levels of thymidylate synthase in their lung tumors experienced greater benefits from treatment with pemetrexed and cisplatin. The enzyme's expression level can also serve as a prognostic biomarker for overall survival.
The phase III trials indicate that anamorelin is safe and well-tolerated in treating symptoms of advanced non-small cell lung cancer anorexia-cachexia. Patients experienced improvements in lean body mass, body weight, and patient symptoms/concerns regarding appetite over 12 weeks.
Researchers report that crizotinib effectively halted tumor growth in 36 of 50 study participants and suppressed it in another 9. The study confirmed that ROS1 is a viable therapeutic target for ROS1-positive lung cancer patients.
A direct comparison of docetaxel and pemetrexed with cisplatin shows similar progression-free survival rates, but docetaxel is associated with more frequent adverse events. The study included 149 patients with non-squamous lung cancer and found that the pemetrexed combination was less toxic.
A substantial proportion of potential subjects are reflexively excluded from lung cancer clinical trials due to prior cancer. The exclusion criterion was applied in more than two-thirds of trials in which survival was not the primary endpoint, resulting in up to 18% exclusion rate.
Researchers found modest acute changes in cardiac biomarkers and electrocardiogram findings following thoracic radiation therapy, but no clinically significant cardiac events. The study suggests that longer follow-up and increased dose range may reveal the impact of radiation on late RT-related toxicity.
A new study found that high-risk individuals screened for early-stage lung cancer using low-dose computed tomography (LDCT) can reduce treatment costs by up to 85%, resulting in a significant reduction in mortality rates and improved patient outcomes. The average cost per-person for LDCT screening was $453, while the mean cost for diag...
A new analysis found that FDG-PET technology is less accurate in diagnosing lung cancer versus benign disease in regions with high rates of histoplasmosis or tuberculosis. Misdiagnosis could lead to unnecessary tests and surgeries, with potential complications and mortality.
A meta-analysis of 70 studies found that fludeoxyglucose F18-PET combined with CT is less accurate for diagnosing lung cancer in areas with endemic infectious lung diseases. The pooled sensitivity was 89%, but specificity was lower (61%) compared to non-endemic regions (77%).
A Yale study found that patients with early-stage non-small cell lung cancer who underwent conventional surgery had better long-term outcomes than those treated with radiosurgery. The study used Medicare billing records of 1,078 patients and found a significant difference in complications and mortality rates between the two groups.
A meta-analysis of 757 Stage IV NSCLC patients found that factors such as timing of metastases and lymph node involvement impact overall survival. The study identified three risk groups with different five-year OS rates, and highlighted the importance of identifying patients who are most likely to benefit from aggressive treatments.
Research found that NSCLC patients who never smoked had a significantly lower risk of developing secondary primary lung cancers (SPLC) compared to current smokers. The study analyzed 1,484 patients and found that five years after diagnosis, current smokers were more likely to develop SPLC.
Researchers present long-term results of RTOG 0236, confirming good primary tumor control and positive 5-year survival rates for patients with inoperable lung cancer. The study found a 40% 5-year survival rate, with seven percent estimated five-year primary tumor failure rate.
A secondary analysis of the National Lung Screening Trial (NLST) data found that both cancer prevalence and positive predictive value of lung cancer screening were higher in the 65+ cohort than in the under-65 cohort. Clinicians should share age-specific estimates of screening benefits and harms with patients to make an informed decision.
Researchers discovered that patients with lung cancer have a higher breath temperature than those without. The study also identified a cut-off value in temperature measurement to accurately diagnose lung cancer.
A combination therapy of two miRNAs, let-7 and miR-34, has been shown to suppress tumor growth in an animal model of non-small-cell lung cancer. The study offers a promising therapeutic avenue for this aggressive malignancy.
Manchester scientists have developed a method to personalize and increase radiotherapy doses for lung cancer patients, potentially improving local control and survival rates. The technique uses intensity modulated radiotherapy (IMRT) to minimize harm to healthy tissue.
Researchers found BIM deletion independently predicts overall and progression-free survival in advanced NSCLC patients, particularly in those treated with EGFR TKIs or chemotherapy. The study suggests considering BIM deletion as a clinical trial stratification factor for Asian NSCLC patients.